142 related articles for article (PubMed ID: 9335081)
1. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder.
Kellner M; Yassouridis A; Jahn H; Wiedemann K
Psychopharmacology (Berl); 1997 Sep; 133(1):55-61. PubMed ID: 9335081
[TBL] [Abstract][Full Text] [Related]
2. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
Ströhle A; Holsboer F; Rupprecht R
Neuropsychopharmacology; 2000 Mar; 22(3):251-6. PubMed ID: 10693152
[TBL] [Abstract][Full Text] [Related]
3. Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone.
Demiralay C; Jahn H; Kellner M; Yassouridis A; Wiedemann K
World J Biol Psychiatry; 2012 Oct; 13(7):526-34. PubMed ID: 22111662
[TBL] [Abstract][Full Text] [Related]
4. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.
Wiedemann K; Jahn H; Yassouridis A; Kellner M
Arch Gen Psychiatry; 2001 Apr; 58(4):371-7. PubMed ID: 11296098
[TBL] [Abstract][Full Text] [Related]
5. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.
Kellner M; Muhtz C; Stark K; Yassouridis A; Arlt J; Wiedemann K
Psychopharmacology (Berl); 2005 Apr; 179(1):310-5. PubMed ID: 15821951
[TBL] [Abstract][Full Text] [Related]
6. Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4).
Zwanzger P; Eser D; Völkel N; Baghai TC; Möller HJ; Rupprecht R; Padberg F
Int J Neuropsychopharmacol; 2007 Apr; 10(2):285-9. PubMed ID: 16817979
[TBL] [Abstract][Full Text] [Related]
7. Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder.
Kellner M; Wiedemann K; Yassouridis A; Levengood R; Guo LS; Holsboer F; Yehuda R
Biol Psychiatry; 2000 Jan; 47(2):107-11. PubMed ID: 10664826
[TBL] [Abstract][Full Text] [Related]
8. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
Zwanzger P; Eser D; Aicher S; Schüle C; Baghai TC; Padberg F; Ella R; Möller HJ; Rupprecht R
Neuropsychopharmacology; 2003 May; 28(5):979-84. PubMed ID: 12700707
[TBL] [Abstract][Full Text] [Related]
9. Neurohormonal responses to cholecystokinin tetrapeptide: a comparison of younger and older healthy subjects.
Flint AJ; Koszycki D; Bradwejn J; Vaccarino FJ
Psychoneuroendocrinology; 2000 Aug; 25(6):633-47. PubMed ID: 10840174
[TBL] [Abstract][Full Text] [Related]
10. CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks.
Hinkelmann K; Yassouridis A; Mass R; Tenge H; Kellner M; Jahn H; Wiedemann K; Wolf K
J Psychiatr Res; 2010 Dec; 44(16):1148-53. PubMed ID: 20451215
[TBL] [Abstract][Full Text] [Related]
11. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K
Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820
[TBL] [Abstract][Full Text] [Related]
12. Growth-hormone response to clonidine in panic disorder patients in comparison to patients with major depression and healthy controls.
Gann H; Riemann D; Stoll S; Berger M; Müller WE
Pharmacopsychiatry; 1995 May; 28(3):80-3. PubMed ID: 7568369
[TBL] [Abstract][Full Text] [Related]
13. Copeptin - A potential endocrine surrogate marker of CCK-4-induced panic symptoms?
Demiralay C; Agorastos A; Yassouridis A; Jahn H; Wiedemann K; Kellner M
Psychoneuroendocrinology; 2017 Feb; 76():14-18. PubMed ID: 27871026
[TBL] [Abstract][Full Text] [Related]
14. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.
van Megen HJ; Westenberg HG; den Boer JA; Slaap B; van Es-Radhakishun F; Pande AC
Psychopharmacology (Berl); 1997 Feb; 129(3):243-8. PubMed ID: 9084062
[TBL] [Abstract][Full Text] [Related]
15. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers.
Koszycki D; Zacharko RM; Le Mellédo JM; Bradwejn J
Depress Anxiety; 1998; 8(1):1-7. PubMed ID: 9750972
[TBL] [Abstract][Full Text] [Related]
16. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
Bradwejn J; Koszycki D; Annable L; Couëtoux du Tertre A; Reines S; Karkanias C
Biol Psychiatry; 1992 Nov; 32(10):903-12. PubMed ID: 1467375
[TBL] [Abstract][Full Text] [Related]
17. Clonidine in respiratory panic disorder subtype.
Valença AM; Nardi AE; Mezzasalma MA; Nascimento I; Lopes FL; Zin WA; Versiani M
Arq Neuropsiquiatr; 2004 Jun; 62(2B):396-8. PubMed ID: 15273833
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges.
Kronenberg G; Berger P; Tauber RF; Bandelow B; Henkel V; Heuser I
Pharmacopsychiatry; 2005 Jan; 38(1):24-9. PubMed ID: 15706463
[TBL] [Abstract][Full Text] [Related]
19. Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males.
Goettel M; Fuertig R; Mack SR; Just S; Sharma V; Wunder A; den Boer J
CNS Drugs; 2023 Dec; 37(12):1099-1109. PubMed ID: 38019356
[TBL] [Abstract][Full Text] [Related]
20. The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4.
Le Mellédo JM; Arthur H; Dalton J; Woo C; Lipton N; Bellavance F; Koszycki D; Boulenger JP; Bradwejn J
J Psychosom Res; 2001 Sep; 51(3):513-20. PubMed ID: 11602221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
